{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T08:02:53Z","timestamp":1778659373430,"version":"3.51.4"},"reference-count":17,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2008,8,26]],"date-time":"2008-08-26T00:00:00Z","timestamp":1219708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2008,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Oral acetylsalicylic acid (aspirin) is the primary antiplatelet therapy in the treatment of acute myocardial infarction and acute coronary syndrome. Methyl salicylate (MS; oil of wintergreen) is compounded into many over-the-counter antiinflammatory muscle preparations and has been shown to inhibit platelet aggregation locally and to be absorbed systemically.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To assess the ability of topically applied MS to inhibit systemic platelet aggregation for patients who are unable to tolerate oral drug therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A randomized, prospective, blinded, crossover study was conducted in 9 healthy men, aged 30-46 years. All subjects ingested 162 mg of aspirin or applied 5 g of 30% MS preparation to their anterior thighs. There was a minimum 2-week washout period between study arms. Blood and urine were collected at baseline and at 6 hours. An aggregometer measured platelet aggregation over time against 5 standard concentrations of epinephrine, and a mean area under the curve (AUC) was calculated. Urinary metabolites of thromboxane B2 were measured by a standard enzyme immunoassay. Differences in and between groups at baseline and 6 hours were tested by the Wilcoxon signed-rank test,<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Baseline platelet aggregation did not differ significantly between the 2 arms of the study (median AUC [% aggregation'min]; binominal confidence intervals): aspirin 183; 139 to 292 versus MS 197; 118 to 445 (p = 0.51). Both aspirin and MS produced statistically significant platelet inhibition; aspirin decreased the AUC from 183; 139 to 292 to 85; 48 to 128 (p = 0.008) and MS decreased the AUC from 197; 118 to 445 to 112; 88 to 306 (p =0.011). No significant difference was detected between baseline and 6-hour thromboxane levels for either aspirin (p = 0.779) or MS (p = 0.327).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Topical MS and oral aspirin both significantly decrease platelet aggregation in healthy human volunteers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1l128","type":"journal-article","created":{"date-parts":[[2008,8,12]],"date-time":"2008-08-12T23:39:50Z","timestamp":1218584390000},"page":"1396-1401","source":"Crossref","is-referenced-by-count":14,"title":["Comparison of Oral Aspirin Versus Topical Applied Methyl Salicylate for Platelet Inhibition"],"prefix":"10.1177","volume":"42","author":[{"given":"David A","family":"Tanen","sequence":"first","affiliation":[{"name":"Department of Emergency Medicine, Naval Medical Center San Diego, San Diego, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D Christopher","family":"Danish","sequence":"additional","affiliation":[{"name":"Emergency Physician, Department of Emergency Medicine, Naval Medical Center San Diego"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline M","family":"Reardon","sequence":"additional","affiliation":[{"name":"Emergency Physician, Department of Emergency Medicine, Naval Medical Center San Diego"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher B","family":"Chisholm","sequence":"additional","affiliation":[{"name":"Emergency Physician, Department of Emergency Medicine, Naval Medical Center San Diego"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J","family":"Matteucci","sequence":"additional","affiliation":[{"name":"Medical Toxicologist, Department of Emergency Medicine, Naval Medical Center San Diego"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert H","family":"Riffenburgh","sequence":"additional","affiliation":[{"name":"Department of Clinical Investigation, Naval Medical Center San Diego"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2008,8,26]]},"reference":[{"key":"bibr1-aph.1L128","first-page":"349","volume":"8607","author":"ISIS-2 (Second International Study of Infarct Survival) Collaborative Group","year":"1988","journal-title":"Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2"},{"key":"bibr2-aph.1L128","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.308.6921.81"},{"key":"bibr3-aph.1L128","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199405053301808"},{"key":"bibr4-aph.1L128","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.88.2.556"},{"key":"bibr5-aph.1L128","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0022-3565(25)12907-8","volume":"277","author":"McAdam B","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"bibr6-aph.1L128","doi-asserted-by":"publisher","DOI":"10.1177\/106002809603000903"},{"key":"bibr7-aph.1L128","doi-asserted-by":"publisher","DOI":"10.1136\/ard.43.3.411"},{"key":"bibr8-aph.1L128","first-page":"67","volume":"162","author":"Born GVR","year":"1962","journal-title":"J Physiol"},{"key":"bibr9-aph.1L128","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-6576.1981.tb01600.x"},{"key":"bibr10-aph.1L128","first-page":"192","volume":"3","author":"Dalvi SS","year":"1985","journal-title":"J Postgrad Med"},{"key":"bibr11-aph.1L128","doi-asserted-by":"publisher","DOI":"10.1378\/chest.126.3_suppl.513S"},{"key":"bibr12-aph.1L128","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1943.01500190019002"},{"key":"bibr13-aph.1L128","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1943.01510040028006"},{"key":"bibr14-aph.1L128","doi-asserted-by":"publisher","DOI":"10.3109\/15563659609013814"},{"key":"bibr15-aph.1L128","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(85)90021-0"},{"key":"bibr16-aph.1L128","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(84)90451-5"},{"key":"bibr17-aph.1L128","doi-asserted-by":"publisher","DOI":"10.1172\/JCI110576"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1L128","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1L128","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:09:48Z","timestamp":1777374588000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1L128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,26]]},"references-count":17,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["10.1345\/aph.1L128"],"URL":"https:\/\/doi.org\/10.1345\/aph.1l128","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,26]]}}}